Gifts Connetics, biotechnology and pharmaceutical companies, since its founding in 1993 through the final clinical trial of its flagship drug compound in 2000. All the while, the company experienced a failure of another compound, while successful in licensing other pharmaceutical products that are immediately profitable. Ultimately, the baseline study in 2000 was a failure and CEO Tom Wiggans to manage the company through this setback (stock went from $ 25 to $ 5, after the results were revealed in public). "Hide
by Robert Chess, Mark Leslie, Joshua Spitzer Source: Stanford Graduate School of Business 26 pages. Publication Date: March 15, 2006. Prod. #: E200-PDF-ENG
